Global pharma giant Lupin has announced a strategic partnership with nonprofit drug developer TB Alliance to accelerate the development and commercialization of Telacebec, a promising treatment for tuberculosis and other mycobacterial diseases, including leprosy and Buruli ulcer.

 

Under the collaboration, TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide.

 

“This collaboration with TB Alliance underscores Lupin’s enduring commitment to improving patient outcomes in areas of significant unmet medical need,” said Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU at Lupin. 

 

“By leveraging our manufacturing scale and global distribution capabilities alongside TB Alliance’s deep expertise in drug development, we aim to enable timely and equitable access to Telacebec and contribute meaningfully to the global fight against tuberculosis, leprosy, and Buruli ulcer.”

 

Mel Spigelman, President and CEO of TB Alliance, added, “Telacebec represents the kind of scientific innovation that has the potential to transform treatment for diseases that have long been neglected. By partnering with Lupin, we are combining deep scientific expertise with global Chemistry, Manufacturing and Controls and access capabilities to help move this promising compound forward as quickly and responsibly as possible, with the ultimate goal of delivering better treatment options to people affected by tuberculosis, leprosy, and Buruli ulcer around the world.”

 

Lupin distributes products in over 100 markets and is recognized for its extensive portfolio across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, CNS, and women’s health.